Advisory Services Network LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 1,075.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,253 shares of the medical equipment provider’s stock after purchasing an additional 24,020 shares during the quarter. Advisory Services Network LLC’s holdings in Hologic were worth $1,122,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Olstein Capital Management L.P. increased its position in shares of Hologic by 23.4% during the fourth quarter. Olstein Capital Management L.P. now owns 147,700 shares of the medical equipment provider’s stock worth $6,314,000 after acquiring an additional 28,000 shares during the period. Toronto Dominion Bank increased its position in shares of Hologic by 11.9% during the fourth quarter. Toronto Dominion Bank now owns 119,035 shares of the medical equipment provider’s stock worth $5,088,000 after acquiring an additional 12,666 shares during the period. Greenleaf Trust increased its position in shares of Hologic by 1.5% during the fourth quarter. Greenleaf Trust now owns 112,101 shares of the medical equipment provider’s stock worth $4,792,000 after acquiring an additional 1,675 shares during the period. NuWave Investment Management LLC purchased a new stake in shares of Hologic during the fourth quarter worth $199,000. Finally, Wealthstreet Investment Advisors LLC purchased a new stake in shares of Hologic during the fourth quarter worth $699,000. 93.84% of the stock is currently owned by institutional investors.
A number of research firms have recently weighed in on HOLX. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Evercore ISI began coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Thursday, February 1st. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective on the stock in a research report on Monday, December 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $48.00.
Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 earnings per share. equities analysts expect that Hologic, Inc. will post 2.25 EPS for the current fiscal year.
In other Hologic news, Director Namal Nawana bought 6,600 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now directly owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2018/02/17/hologic-inc-holx-shares-bought-by-advisory-services-network-llc.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.